Zhejiang Haisen Pharmaceutical Co., Ltd. 2025 Annual Report Summary
Securities Code: 001367 Securities Abbreviation: Haisen Pharmaceutical Announcement No.: 2026-003
I. Important Notes
This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard Audit Opinion Notice □ Applicable Not Applicable
Board of Directors' Review of Profit Distribution Plan or Capital Reserve Transfer to Share Capital Plan for the Reporting Period ☑ Applicable Not Applicable
Is Capital Reserve Transferred to Share Capital? □ Yes No
The profit distribution plan reviewed and approved by the Board of Directors for the current period is as follows: Based on the total share capital on the equity registration date for the 2025 annual distribution, a cash dividend of 1.16 yuan (tax inclusive) per 10 shares will be distributed to all shareholders, with 0 bonus shares (tax inclusive), and no capital reserve will be transferred to share capital.
Board of Directors' Resolution on Preferred Stock Profit Distribution Plan for the Reporting Period □ Applicable Not Applicable
II. Basic Company Information
- Company Profile
| Stock Abbreviation | Stock Listing Exchange | Stock Code | 001367 |
|---|---|---|---|
| Haisen Pharmaceutical | Shenzhen Stock Exchange |